This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In the ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial, researchers examined the risk of ischemic events in patients with stable coronaryarterydisease. Original article: Redfors B et al.
milla1cf Tue, 01/09/2024 - 11:32 January 9, 2024 — Cleerly , the company working to create a new standard of care for the diagnosis of heart disease, announced the launch of Cleerly ISCHEMIA , which recently received U.S. Cleerly ISCHEMIA is a transformative addition poised to reshape the landscape of cardiac care.”
Ischemia and no obstructive coronaryarterydisease (INOCA) is increasingly recognized and associated with poor outcomes. The triglyceride-glucose (TyG) index is a reliable alternative measure of insulin resis.
milla1cf Fri, 02/23/2024 - 11:54 February 23, 2024 — Cleerly , the company creating a new standard of care to aid in the diagnosis of heart disease, announced that its recently U.S. Prior studies have demonstrated the independent and incremental benefit of Cleerly ISCHEMIA applied to CCTA beyond traditional assessment.
It further reported that these results underscore the strong and positive effect of the Cleerly products on clinical utility for patients with suspected coronaryarterydisease. “We High Diagnostic Accuracy Of AI-Ischemia in Comparison To PET, FFR-CT, SPECT, and Invasive FFR: A PACIFIC Sub-Study. James Min, M.D.
Together, the two companies will work to further the development and commercialization of Medis Quantitative Flow Ratio (Medis QFR), a non-invasive approach to the assessment of coronary physiology, as part of GE HealthCare’s interventional cardiology portfolio built around the Allia Platform.
a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint results of the open label roll-in cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial. million patients in the United States.
In 2024, the FDA approved Flyrcado for patients with known or suspected coronaryarterydisease (CAD), delivering higher diagnostic efficacy compared to single-photon emission computed tomography (SPECT) i myocardial perfusion imaging (MPI), the predominant procedure used in nuclear cardiology today. 2023 Oct, 82 (16) 15981610.
Hemodynamic reactivity, changes in endothelial function, and vasoconstriction during mental stress were evaluated using changes in ratepressure product, brachial artery flowmediated vasodilation, and peripheral arterial tonometry, respectively.
Coronaryartery bypass grafting (CABG) is a surgical procedure that improves blood flow to the heart tissue and can effectively treat myocardial ischemia caused by coronaryarterydisease.
milla1cf Thu, 03/28/2024 - 07:00 March 28, 2024 — Cleerly , the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, shared findings from a study published online in the Journal of the American College of Cardiology: Cardiovascular Imaging on March 13, 2024. J Am Coll Cardiol. 2024.01.007.
1 Atherosclerosis is a systemic disease that affects multiple vascular regions and is particularly severe in PAD patients, where up to 80 percent suffer from concurrent coronaryarterydisease (CAD), historically linked with a mortality rate exceeding 50 percent within five years. Journal of Vascular Surgery, Mar.
This case shows a CT image of subendocardial ischemia. ng/mL (slightly elevated) and his symptoms could not be controlled with nitroglycerin, so he was taken to the cath lab and found to have: --Severe 3 vessel Coronaryarterydisease involving the LM. The image is shown at the bottom after the case presentation.
A study in the Journal of Vascular Surgery revealed that adding FFRCT assessments to patient workups prior to peripheral arterydisease surgeries has a massive impact on coronaryarterydisease detection, treatments, and long-term outcomes.
Many of the changes seen are reminiscent of LVH with “strain,” and downstream Echo may very well corroborate such a suspicion, but since the ECG isn’t the best tool for definitively establishing the presence of LVH, we must favor a subendocardial ischemia pattern, instead. Type I ischemia. Type II ischemia.
Owing to its unique location and multifaceted metabolic functions, epicardial adipose tissue (EAT) is gradually emerging as a new metabolic target for coronaryarterydisease risk stratification. Microvascular.
PCI is commonly used to open blocked arteries to treat significant myocardial ischemia , which occurs when the heart muscle does not get enough oxygenated blood. To test this strategy, researchers enrolled 1,606 patients treated for coronaryarterydisease at 15 centers in four countries.
Food and Drug Administration (FDA) for its DynamX BTK System, a novel, adaptive implant for use in the treatment of narrowed or blocked vessels below-the-knee (BTK) in patients with chronic limb-threatening ischemia (CLTI). The natural history of untreated severe or critical limb ischemia. 2013;382(9901):1329-1340. J Vasc Surg.
Traditional methods of non-invasive ischemia testing (stress EKG , stress echo, SPECT , PET , direct-to-cath) can result in false negatives 20-30 percent of the time, which can lead to undetected disease, and false positives over 50 percent of the time, which can lead to unnecessary invasive procedures.
The Freesolve BTK RMS is designed for individuals suffering from chronic limb-threatening ischemia (CLTI). CLTI is the most severe form of peripheral arterialdisease (PAD), estimated to affect 11% of the 200 million people suffering from PAD globally. Jörg Pochert, President of Vascular Intervention at Biotronik.
Important point: when there is diffuse subendocardial ischemia but no OMI, a wall motion abnormality will not necessarily be present. They agreed ischemia was likely in the setting of demand given DKA and infection. That this is all demand ischemia is unlikely. Lung exam showed diffuse B lines bilaterally. Aslanger's pattern.
Background:Myocardial infarction with nonobstructive coronaryarterydisease (MINOCA) is a special syndrome with clear evidence of myocardial ischemia, but no clear stenosis of coronaryartery imaging sign. Circulation, Volume 150, Issue Suppl_1 , Page A4143007-A4143007, November 12, 2024.
The most likely cause of this type of polymorphic ventricular tachycardia during a stress EKG is cardiac ischemia/coronaryarterydisease. The QT interval of the sinus beats does not appear prolonged, thus ruling out Torsades de Pointes tachycardia.
Risk factors for PAD include smoking; having Type 1 or Type 2 diabetes, high blood pressure, high cholesterol, chronic kidney disease, atherosclerosis in other parts of the body (such as coronaryarterydisease); and being age 75 years or older. It has been estimated that less than 5% of patients with PAD in the U.S.
milla1cf Wed, 03/06/2024 - 18:48 March 6, 2024 — Cleerly , the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration ( FDA ) for its CoronaryArteryDisease ( CAD ) Staging System.
Background Refractory angina (RA) is a chronic condition characterized by the presence of debilitating angina symptoms due to established reversible ischemia in the presence of obstructive coronaryarterydisease (CAD).
I quickly reviewed the patient’s records and saw that she was a 53 year old woman with a history of BMI 40, but no other identifiable risk factors for coronaryarterydisease. This proves effective treatment of the recurrent ischemia. The patient had no further symptoms of ischemia.
Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronaryarterydisease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3
The diagnostic coronary angiogram identified only minimal coronaryarterydisease, but there was a severely calcified, ‘immobile’ aortic valve. DISCUSSION: The 12-lead EKG EMS initially obtained for this patient showed severe ischemia, with profound "infero-lateral" ST depression and reciprocal ST elevation in lead aVR.
The first task when assessing a wide complex QRS for ischemia is to identify the end of the QRS. The ST segment changes are compatible with severe subendocardial ischemia which can be caused by type I MI from ACS or potentially from type II MI (non-obstructive coronaryarterydisease with supply/demand mismatch).
By Magnus Nossen, edits by Grauer and Smith The patient is a 70-something female with DMII, HTN and an extensive prior history of coronaryarterydisease and myocardial infarctions. ECG#1 Assessing ischemia on an ECG with wide QRS complexes (AIVR, ventricular pacing, BBB, etc) can be challenging. What do you think?
In general, there is no debate here regarding the need for stenting a coronaryartery. Share Stenting In Stable CoronaryArteryDisease The real debate relates to the role of stenting in the setting of a severely narrow coronaryartery outside the setting of a heart attack. Makes total sense.
Introduction The use of contemporary drug-eluting stents (DES) has significantly improved outcomes of patients with coronaryarterydisease (CAD) undergoing percutaneous coronary intervention (PCI). had multivessel disease (MVD) and in 3.3% At 1 year, only two (0.5%) subjects presented ischemia-driven TLR.
In this study, we aimed to evaluate the prognostic value of ΔLVEF when acquired by SPECT G-MPI in patients with coronaryarterydisease (CAD) and a LVEFStress 0% and ΔLVEF ≤ 0%), and survival analyses were conducted.
ObjectiveA significant proportion (85%) of low-risk non-ST-elevation acute coronary syndrome (NSTE-ACS) patients do not receive objective confirmation of ischemia by stress echocardiography (SE), yet remain a healthcare burden due to lower long-term survival and overuse of medical services.
indicates inducible ischemia while an FFR above 0.80 excludes ischemia in 90% of cases. FAME study showed that at one year follow up, rate of major adverse coronary events was reduced by approximately 30% by routinely measuring FFR. There is a strong correlation between FFR and inducible myocardial ischemia. in the study.
Heart Valve Disease If one or more heart valves are not functioning correctly, it can cause blood to flow backward, putting extra pressure on the heart, which may cause it to expand to compensate for the inefficiency. This may result in ischemia (lack of oxygen to the heart muscle), causing parts of the heart to weaken and enlarge.
This highlights the need for serial ECGs in acute coronary syndrome as initial ECGs may be near normal even in those with severe disease. Classical electrocardiographic pattern in left main coronaryarterydisease is ST elevation in aVR with extensive ST depression in other leads, most prominent in I, II and V4-V6.
There is no definite evidence of acute ischemia. (ie, Simply stated — t he patient was having recurrent PMVT without Q Tc prolongation, and without evidence of ongoing transmural ischemia. ( If there had been ECG findings indicating reocclusion of the artery — an angiogram would have been warranted ).
CT coronary angiography, in addition to a CT CAC, is arguably the best test for estimating whether someone has evidence of coronaryarterydisease and what that means for their near-term risk of a heart attack. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. N Engl J Med.
25, 2025 GE HealthCare has delivered the first patient doses of Flyrcado(flurpiridaz F 18) injection, a unit dose positron emission tomography myocardial perfusion imaging (PET MPI) agent for detecting coronaryarterydisease (CAD), at early adopter imaging centers in the US. tim.hodson Mon, 03/03/2025 - 16:07 Feb.
His response: “subendocardial ischemia. Smith : It should be noted that, in subendocardial ischemia, in contrast to OMI, absence of wall motion abnormality is common. With the history of Afib, CTA abdomen was ordered to r/o mesenteric ischemia vs ischemic colitis vs small bowel obstruction. Anything more on history?
Angiogram No obstructive epicardial coronaryarterydisease Cannot exclude non-ACS causes of troponin elevation including coronary vasospasm, stress cardiomyopathy, microvascular disease, etc. Detailed coronaryartery evaluation not performed. This suggests further severe ischemia.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content